AMV564-101 is a phase 1, first-in-human, dose escalation and dose expansion trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMV564 in patients with relapsed or refractory acute myeloid leukaemia (AML) after 1-2 prior induction regimens (with a standard anthracycline-based regimen or hypomethylating agent) and no more than 2 prior salvage regimens. Prof. Gail Roboz (Weill Cornell Medicine, USA) highlighted initial data from the dose-escalation portion of data from 33 patients treated within 9 cohorts, demonstrating favourable safety profile and initial efficacy data that AMV564 is active .
AMV564 is a bivalent, bispecific CD33/CD3 T cell engager with 2 binding sites for CD3 (expressed on T cells) and 2 binding sites for CD33 (highly expressed in myeloid-derived suppressor cells and on >95% of AML blasts). AMV564 brings T c...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma Next Article
Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.